Peregrine Pharmaceuticals reported $27.58M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Agenus AGEN:US $ 2.02M 1.48M
Amgen AMGN:US $ 1510M 51M
AstraZeneca AZN:LN 156386.94M 17145.23M
Biocryst Pharmaceuticals BCRX:US $ 0.25M 0.01M
Bristol Myers Squibb BMY:US $ 2677M 206M
ChemoCentryx CCXI:US 803K 598K
Eli Lilly And LLY:US $ 1430.5M 641.6M
GlaxoSmithKline GSK:LN 213600M 55400M
Intrexon XON:US $ 1.81M 15.29M
Karyopharm Therapeutics KPTI:US $ 939K 487K
MacroGenics MGNX:US 2.4M 2.35M
Mannkind MNKD:US $ 12.92M 1.92M
Merk MRK:US $ 3698M 1636M
Novartis NOVN:VX SF 3749M 6M
Novavax NVAX:US 271.08M 255.87M
Peregrine Pharmaceuticals PPHM:US $ 27.58M 3.33M
Repligen RGEN:US $ 86.26M 3.9M